Search Within

Andrew D Zelenetz

  1. "2004"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (10)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Lymphoma (25)
  5. Radiation Oncology, Department of (8)
  6. Survivorship Research (8)

More Groups

People
  1. Craig Moskowitz (12)
  2. David Straus (8)
  3. Joachim Yahalom (8)
  4. Carol Portlock (6)
  5. Julie Feldstein (6)
  6. Owen O'connor (6)

More People

Years
  1. 2004 (25)
Publications
  1. Blood (14)
  2. Journal of Clinical Oncology (3)
  3. British Journal of Haematology (2)
  4. Journal of the National Comprehensive Cancer Network (2)
  5. Annals of Oncology (1)
  6. Applied Immunohistochemistry & Molecular Morphology (1)

More Publications

Publishers
  1. American Society of Hematology (14)
  2. American Society of Clinical Oncology (3)
  3. Harborside Press (2)
  4. John Wiley & Sons (2)
  5. American Association for Cancer Research (1)
  6. Elsevier Inc. (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes and cost of outpatient community-based treatment for rituximab refractory non-Hodgkins Lymphoma (NHL) patients
    Meeting Abstract

    Zelenetz, A. D.; Tang, B. X.; Frame, D.; Nalysnyk, L.; Cella, C.; Noel, J. K.
    Blood (2004)

    Fulltext@MSK | Save
  • A Multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition
    Meeting Abstract

    O'connor, O.; Wright, J.; Moskowitz, C.; Macgregor-Cortelli, B.; Straus, D.; Evans, A.; Winter, J.; Koc, O.; Horvath, N.; Blumel, S.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • The importance of molecular phenotype in predicting overall survival in patients with relapsed or primary refractory DLBCL treated with second-line chemotherapy and ASCT
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Hamlin, P.; Nimer, S. D.; Zelenetz, A. D.; Teruya-Feldstein, J.
    Blood (2004)

    Fulltext@MSK | Save
  • Routine imaging identifies a group of patients with more favorable aggressive NHL at relapse: A retrospective study of a uniformly treated patient population
    Meeting Abstract

    Liedtke, M.; Moskowitz, C. H.; Hamlin, P. A.; Zelenetz, A. D.
    Blood (2004)

    Fulltext@MSK | Save
  • Impact of course of therapy on response rate and duration with the Bexxar® therapeutic regimen (tositumomab and iodine I 131 tositumomab) and with chemotherapy
    Meeting Abstract

    Leonard, J. P.; Zelenetz, A. D.; Vose, J. M.; Kaminski, M. S.
    Blood (2004)

    Fulltext@MSK | Save
  • Tositumomab and iodine I 131 tositumomab (BEXXAR (R) therapeutic regimen) produces long-term durable responses in heavily pretreated patients with relapsed, refractory, and transformed low-grade non-hodgkin's lymphoma (NHL
    Meeting Abstract

    Knox, S. K.; Meredith, R. F.; Coleman, M.; Kaminski, M. S.; Zelenetz, A. D.; Vose, J. M.
    International Journal of Radiation Oncology, Biology, Physics (2004)

    Fulltext@MSK | Save
  • Tositumomab and iodine I 131 tositumomab (The BEXXAR (R) therapeutic regimen) produced ongoing, durable remissions of more than 5 years in 9 patients with non-Hodgkin's lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy
    Meeting Abstract

    Kaminski, M. S.; Zelenetz, A. D.; Press, O. W.; Saleh, M. N.; Leonard, J. P.; Fehrenbacher, L.; Lister, T. A.; Kroll, S.; Wahl, R. L.; Knox, S. J.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Primary Mediastinal Large B cell Lymphoma: Elucidating optimal therapy and prognostic factors; an analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980-1999
    Meeting Abstract

    Hamlin, P. A.; Portlock, C. S.; Straus, D. J.; Noy, A.; Horwitz, S. M.; O'connor, O.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
    Blood (2004)

    Fulltext@MSK | Save
  • The follicular lymphoma international prognostic index (FLIPI) is superior to WHO/REAL histological grade for identifying high-risk patients: A retrospective review of the MSKCC experience in 260 patients with follicular lymphoma
    Meeting Abstract

    Halaas, J. L.; Teruya-Feldstein, J.; Filippa, D. A.; Moskowitz, C.; Naresh, K. N.; Zelenetz, A. D.
    Blood (2004)

    Fulltext@MSK | Save
  • Feasibility and preliminary efficacy of R-CHOP-14 in patients with diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Halaas, J. L.; Moskowitz, C. H.; Noy, A.; Portlock, C.; Horwitz, S.; Straus, D.; O'connor, O.; Yahalom, J.; Zelenetz, A. D.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save